EUCTR2011-006125-14-HU进行中（未招募）不适用
A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS - FUNCTION LTE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 241
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet the following criteria for study entry:
- •1.Able and willing to provide written informed consent and to comply with the requirements of the study protocol
- •2.Age = 18 years
- •3.Patients who complete their last WA19926 core study visit (Week 104) and who may benefit from study drug treatment according to the Investigator’s assessment
- •4.No current or recent AE or laboratory finding preventing the use of TCZ 8 mg/kg at screening
- •5.Receiving treatment on an outpatient basis
- •6.For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use at least one adequate method of contraception, including at least one method with a failure rate of < 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period
- •7.Females of child-bearing potential must have a negative serum pregnancy test at screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet any of the following criteria will be excluded from study entry:
- •1. Females who are pregnant
- •2.Patients who have prematurely withdrawn from the WA19926 core study for any reason
- •3.Treatment with any investigational agent or cell depleting therapies since the last administration of study drug in the WA19926 core study
- •4.Treatment with an anti-TNF or anti-IL1 agent, or a T-cell costimulation modulator since the last administration of study drug in the WA19926 core study
- •5.Immunization with a live/attenuated vaccine since the last administration of study drug in the WA19926 core study
- •6.Diagnosis since the last WA19926 visit (Week 104) of rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, and polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome and/or nodulosis with RA are permitted
- •7.Diagnosis since the last WA19926 core study visit (Week 104) of inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease)
- •8.Laboratory parameters at baseline visit (4 to 12 weeks after the last administered dose of study drug in the WA19926 core study):
- •a.AST or ALT = 1.5 times the upper limit of normal (ULN)
- •b.Total Bilirubin > ULN
- •c.Absolute neutrophil count < 1000/mm3 (1 x 10 9/L)
- •d.Platelet count < 100 000/mm3 (100 x 10 9/L)
- •9.History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- •10.Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), immunologic or gastrointestinal disease; history of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower gastrointestinal (GI) disease such as Crohn’s disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations for whom a favorable benefit/risk assessment for study continuation cannot be documented
- •11.Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, clinically significant abnormalities on chest X-ray [CXR] as determined by the Investigator, human immunodeficiency virus [HIV], hepatitis B [hepatitis B surface antigen {HBsAg} and total hepatitis B core antibody {HBcAb}] and hepatitis C virus [HCV] antibody (Ab) and Herpes zoster, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within four weeks prior to baseline or oral antibiotics within two weeks prior to baseline
- •12.Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematological malignancies and solid tumors, except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years
- •13.Uncontrolled disease states, such as asthma or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
- •14.Current liver disease as determined by the Investigator
- •15.Active tuberculosis (TB) requiring treatment within the prev
研究者
相似试验
进行中（未招募）
1 期
A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10028423Term: Myasthenia gravis-like syndromeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10071942Term: Myasthenia gravis and related conditionsSystem Organ Class: 100000004859EUCTR2018-002133-37-BEargenx BVBA145
进行中（未招募）
1 期
A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10028423Term: Myasthenia gravis-like syndromeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10071942Term: Myasthenia gravis and related conditionsSystem Organ Class: 100000004859Myasthenia GravisEUCTR2018-002133-37-CZargenx BVBA150
进行中（未招募）
1 期
A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10028423Term: Myasthenia gravis-like syndromeSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10071942Term: Myasthenia gravis and related conditionsSystem Organ Class: 100000004859Myasthenia GravisEUCTR2018-002133-37-ITARGEN-X BVBA145
已完成
3 期
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX 113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle WeaknessGeneralized Muscle Weakness10003816Myasthenia GravisNL-OMON55635argenx BVBA10
进行中（未招募）
1 期
A safety and tolerability study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.Myasthenia GravisEUCTR2018-002133-37-DEargenx BVBA145